Viragen, AFG BioSolutions to work on biowarfare research

By Elaine Rigoli

Tampa, Fla., May 9 - Viragen, Inc. said it has entered into a research collaboration with AFG BioSolutions, Inc., a prominent biodefense consultant to the U.S. federal government.

AFG BioSolutions has agreed to conduct in-vivo research studies using Multiferon (natural, human alpha interferon) to evaluate its utility as a broad-acting antiviral agent against a variety of biological threats such as smallpox and other biowarfare viral threat agents, according to a news release.

As Viragen builds its Multiferon business across Europe, positioning it as an adjuvant treatment for high-risk malignant melanoma, it will continue to pursue cost-effective programs to expand the indications for interferon technologies worldwide, officials said.

Viragen is a Plantation, Fla.-based biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers.

AFG Biosolutions, located in Germantown, Md., develops candidates for vaccines, antibodies and other therapeutic and prophylactic preparations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.